CN109475121B - 苏比替罗衍生物 - Google Patents

苏比替罗衍生物 Download PDF

Info

Publication number
CN109475121B
CN109475121B CN201780043724.6A CN201780043724A CN109475121B CN 109475121 B CN109475121 B CN 109475121B CN 201780043724 A CN201780043724 A CN 201780043724A CN 109475121 B CN109475121 B CN 109475121B
Authority
CN
China
Prior art keywords
disease
pharmaceutically acceptable
acceptable salt
brain
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780043724.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109475121A (zh
Inventor
T·斯坎兰
J·德维雷奥克斯
A·普拉泽克
T·班纳基
S·费拉拉
J·M·迈尼希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health & Science University
Original Assignee
Oregon Health & Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University filed Critical Oregon Health & Science University
Priority to CN202110619632.6A priority Critical patent/CN113277958A/zh
Publication of CN109475121A publication Critical patent/CN109475121A/zh
Application granted granted Critical
Publication of CN109475121B publication Critical patent/CN109475121B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/62—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/115—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/06—Alkylated phenols
    • C07C39/07—Alkylated phenols containing only methyl groups, e.g. cresols, xylenols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/16—Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/30—Compounds having groups
    • C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/34—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
CN201780043724.6A 2016-05-18 2017-05-18 苏比替罗衍生物 Active CN109475121B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110619632.6A CN113277958A (zh) 2016-05-18 2017-05-18 苏比替罗衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338178P 2016-05-18 2016-05-18
US62/338,178 2016-05-18
PCT/US2017/033388 WO2017201320A1 (en) 2016-05-18 2017-05-18 Derivatives of sobetirome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110619632.6A Division CN113277958A (zh) 2016-05-18 2017-05-18 苏比替罗衍生物

Publications (2)

Publication Number Publication Date
CN109475121A CN109475121A (zh) 2019-03-15
CN109475121B true CN109475121B (zh) 2021-06-25

Family

ID=60326251

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780043724.6A Active CN109475121B (zh) 2016-05-18 2017-05-18 苏比替罗衍生物
CN202110619632.6A Pending CN113277958A (zh) 2016-05-18 2017-05-18 苏比替罗衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110619632.6A Pending CN113277958A (zh) 2016-05-18 2017-05-18 苏比替罗衍生物

Country Status (20)

Country Link
US (3) US10544075B2 (enExample)
EP (2) EP3457851B1 (enExample)
JP (2) JP6982004B2 (enExample)
KR (1) KR102331596B1 (enExample)
CN (2) CN109475121B (enExample)
AU (1) AU2017267734B2 (enExample)
CY (1) CY1124704T1 (enExample)
DK (1) DK3457851T3 (enExample)
ES (1) ES2888915T3 (enExample)
HR (1) HRP20211429T1 (enExample)
HU (1) HUE056357T2 (enExample)
IL (1) IL263050B (enExample)
LT (1) LT3457851T (enExample)
MX (1) MX382313B (enExample)
PL (1) PL3457851T3 (enExample)
PT (1) PT3457851T (enExample)
RS (1) RS62408B1 (enExample)
SI (1) SI3457851T1 (enExample)
SM (1) SMT202100551T1 (enExample)
WO (1) WO2017201320A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180021A1 (es) 2015-02-20 2018-01-09 Univ Oregon Health & Science Derivados de sobetiroma
AU2017252126B2 (en) 2016-04-22 2023-02-09 Metabasis Therapeutics, Inc. Use of thyroid beta-agonists
CN109641003A (zh) * 2016-04-22 2019-04-16 维京治疗股份有限公司 甲状腺β-激动剂的应用
MX382313B (es) 2016-05-18 2025-03-13 Univ Oregon Health & Science Derivados del sobetiroma.
MX2020008498A (es) 2018-02-14 2020-09-25 Univ Oregon Health & Science Derivados de sobetirome.
EP3894383A1 (en) * 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
CN115279359A (zh) * 2019-11-29 2022-11-01 速通医疗公司 新型拟甲状腺素药
EP4168384A4 (en) * 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
WO2021257834A1 (en) * 2020-06-17 2021-12-23 Autobahn Therapeutics, Inc. Thyromimetics
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
CN117597122A (zh) * 2021-05-06 2024-02-23 速通医疗公司 拟甲状腺素药的脂肪酸酰胺水解酶(faah)可裂解前药以及与外周限制性faah抑制剂的组合
AU2022271304A1 (en) * 2021-05-06 2023-11-23 Autobahn Therapeutics, Inc. Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitors
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431163A (zh) * 2013-05-03 2016-03-23 俄勒冈健康科学大学 索布替罗用于治疗髓鞘形成疾病

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
JP2002519340A (ja) * 1998-06-30 2002-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 甲状腺ホルモン類似体およびそれらの調製方法
EP1194422A1 (en) * 1999-06-01 2002-04-10 University Of Texas Southwestern Medical Center Biaryl compounds
PL201790B1 (pl) * 2000-02-17 2009-05-29 Bristol Myers Squibb Co Anilinopochodny ligand dla receptora tarczycy, jego zastosowanie i kompozycja farmaceutyczna
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
US20090232879A1 (en) * 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
JP5847533B2 (ja) * 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
PE20180021A1 (es) * 2015-02-20 2018-01-09 Univ Oregon Health & Science Derivados de sobetiroma
WO2017015360A1 (en) 2015-07-20 2017-01-26 Oregon Health & Science University Quinolone-3-diarylethers
MX382313B (es) 2016-05-18 2025-03-13 Univ Oregon Health & Science Derivados del sobetiroma.
WO2018208707A1 (en) 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431163A (zh) * 2013-05-03 2016-03-23 俄勒冈健康科学大学 索布替罗用于治疗髓鞘形成疾病

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Smoldering and polarized inflammation in the initiation and promotion of malignant disease;Frances Balkwill et,al.;《cancer cell》;20050331;第7卷;第211-217页 *
Sobetirome及MK-8033的合成研究;刘宁;《中国优秀硕士学位论文 工程科技辑第I辑》;20150115;B016-380 *
The resurgence of thyromimetics as lipid-modifying agents;I Tancevski et,al.;《Curr Opin Investig Drugs. Author manuscript》;20090930;第10卷(第9期);第912-918页 *

Also Published As

Publication number Publication date
RS62408B1 (sr) 2021-10-29
WO2017201320A1 (en) 2017-11-23
JP6982004B2 (ja) 2021-12-17
KR102331596B1 (ko) 2021-11-25
US20190210950A1 (en) 2019-07-11
JP2019516739A (ja) 2019-06-20
MX382313B (es) 2025-03-13
SMT202100551T1 (it) 2022-01-10
CA3024680A1 (en) 2017-11-23
EP3936497A1 (en) 2022-01-12
RU2018142863A (ru) 2020-06-18
HRP20211429T1 (hr) 2021-12-10
HUE056357T2 (hu) 2022-02-28
US20240425437A1 (en) 2024-12-26
US20200325092A1 (en) 2020-10-15
NZ748895A (en) 2024-12-20
BR112018073679A2 (pt) 2019-02-26
KR20190006012A (ko) 2019-01-16
LT3457851T (lt) 2021-10-11
CN109475121A (zh) 2019-03-15
US10870616B2 (en) 2020-12-22
PL3457851T3 (pl) 2022-03-14
PT3457851T (pt) 2021-09-28
US10544075B2 (en) 2020-01-28
MX2018014114A (es) 2019-07-10
IL263050A (en) 2018-12-31
CN113277958A (zh) 2021-08-20
RU2018142863A3 (enExample) 2020-07-13
IL263050B (en) 2021-09-30
SI3457851T1 (sl) 2022-04-29
CY1124704T1 (el) 2022-07-22
DK3457851T3 (da) 2021-09-20
EP3457851A4 (en) 2020-02-26
AU2017267734B2 (en) 2021-09-09
AU2017267734A1 (en) 2018-12-20
EP3457851B1 (en) 2021-06-23
JP2022033788A (ja) 2022-03-02
ES2888915T3 (es) 2022-01-10
EP3457851A1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
US20240425437A1 (en) Derivatives of sobetirome
US12358875B2 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis
EP3259246B1 (en) Derivatives of sobetirome
US11578032B2 (en) Derivatives of sobetirome
CA2517893C (fr) Application a titre de medicaments de derives de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation
US11337941B2 (en) Inhibitors and their uses
CN102112441B (zh) 吲哚衍生物作为nurr-1激活剂治疗帕金森病的用途
HK40005534A (en) Derivatives of sobetirome
US20230348364A1 (en) Isotopic thyromimetic compounds
RU2776372C2 (ru) Производные собетирома
KR102784482B1 (ko) 신경퇴행성 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
HK40005534B (en) Derivatives of sobetirome
CN114502160A (zh) 钙蛋白酶抑制剂及其用于治疗神经病症的用途
BR112018073679B1 (pt) Compostos derivados halo-substituídos do sobetirome com características farmacológicas aprimoradas
HK40039586A (en) Derivatives of sobetirome
JPWO2014030624A1 (ja) スチルベン誘導体を有効成分として含有する筋緊張性ジストロフィー治療剤
JP2010077081A (ja) 体内時計周期延長剤およびそれを含む概日リズム障害治療薬
HK1247182A1 (en) Derivatives of sobetirome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005534

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant